Depression trials recruiting in Washington

All Depression trials nationally

Cities in Washington

Recruiting trials in Washington

• A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
  NCT07592689 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Washington: Seattle, Vancouver
• A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
  NCT03887715 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Washington: Mercer Island, Seattle
• A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
  NCT07172516 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Washington: Everett
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
  NCT06775379 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Washington: Everett
• A Study of Brenipatide in Adult Participants With Major Depressive Disorder
  NCT07412756 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Washington: Bellevue
• A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
  NCT07573176 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Washington: Bellevue
• A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
  NCT06793397 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · Washington: Everett, Seattle
• A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
  NCT06696755 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Washington: Bellevue, Everett
• A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
  NCT04777357 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · Washington: Everett
• A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
  NCT07276997 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Washington: Bellevue, Everett
• A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
  NCT06524830 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Washington: Bellevue
• A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
  NCT07610473 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Washington: Bellevue, Seattle
• A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
  NCT07300969 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Washington: Bellevue
• A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
  NCT07065240 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Washington: Everett
• A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
  NCT06223880 · Phase: Phase 4 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Washington: Everett
• ALTO-207 in Adults With Treatment-resistant Depression (TRD)
  NCT07553637 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Washington: Seattle
• CBT-I vs. MBTI for Traumatic Brain Injury (TBI)-Related Insomnia and Post-Traumatic Stress Symptoms
  NCT05663034 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Washington: Fort Lewis
• Deep Brain Stimulation of Treatment-Resistant Bipolar Depression
  NCT06599099 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 64 Years · Sex: All (male and female) · Washington: Seattle
• E-Mindfulness Approaches for Living After Breast Cancer
  NCT06748222 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: All (male and female) · Washington: Silverdale
• Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
  NCT06830044 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Washington: Bellevue
• InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI
  NCT06005194 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 64 Years · Sex: All (male and female) · Washington: Seattle
• Lay-Delivered Behavioral Activation in Senior Centers
  NCT04621877 · Phase: Not applicable (e.g. observational or device study) · Ages: 60 Years and older · Sex: All (male and female) · Washington: Enumclaw, Seattle, Tacoma
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06966401 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Everett
• Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
  NCT06372964 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · Washington: Bellevue, Everett
• Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
  NCT07494305 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Washington: Bellevue
• PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
  NCT06713616 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Seattle
• Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
  NCT06559306 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Washington: Everett
• Positive Processes and Transition to Health (PATH)
  NCT06093906 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 65 Years · Sex: All (male and female) · Washington: Seattle
• Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
  NCT07226232 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Washington: Seattle
• RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
  NCT07002034 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Washington: Seattle
• Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
  NCT06633016 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Washington: Bellevue
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
  NCT05850689 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Washington: Bellevue
• Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06786624 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Washington: Everett
• TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age
  NCT07048574 · Phase: Not specified · Ages: 18 Months to 11 Years · Sex: All (male and female) · Washington: Seattle
• The OBSERVE Protocol
  NCT06725277 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Washington: Seattle
• Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus
  NCT06232304 · Phase: Not applicable (e.g. observational or device study) · Ages: 12 Years to 22 Years · Sex: All (male and female) · Washington: Seattle
• Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
  NCT06547489 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · Washington: Bellevue